– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces – Expected ...
AIM ImmunoTech Inc. announced its participation in the Virtual Investor “Top 5 for ‘25” On-Demand Conference, where CEO Thomas K. Equels highlighted five key areas deserving investor attention in 2025 ...
OCALA, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted key clinical, regulatory and corporate milestones achieved over 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results